News & Updates
Filter by Specialty:
Trabectedin fails to improve survival outcomes in recurrent ovarian, primary peritoneal, or fallopian tube cancer
07 Sep 2022
byRoshini Claire Anthony
Trabectedin did not improve overall survival (OS) or progression-free survival (PFS) compared with chemotherapy in women with recurrent ovarian, primary peritoneal, or fallopian tube cancer and BRCA mutation or BRCAness phenotypes, according to results of the phase III MITO23 trial.
Trabectedin fails to improve survival outcomes in recurrent ovarian, primary peritoneal, or fallopian tube cancer
07 Sep 2022IV, SC doses of biologic combo effective in asymptomatic, low-risk COVID-19 patients
07 Sep 2022
All intravenous (IV) and subcutaneous (SC) doses of the monoclonal antibody combination of casirivimab plus imdevimab effectively reduces viral load in COVID-19 patients with asymptomatic or low-risk symptomatic infection, according to the results of a phase II study.